TNGX FY 2022 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$25M-32.9% YoY

Gross Profit

$25M100.0% margin

Operating Income

-$111M-446.8% margin

Net Income

-$108M-435.1% margin

EPS (Diluted)

$-1.23

Cash Flow

Operating Cash Flow

-$109M

Free Cash Flow

-$117M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$436M

Total Liabilities

$187M

Stockholders' Equity

$249M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$37M	-32.9%
Gross Profit	$25M	$37M	-32.9%
Operating Income	-$111M	-$58M	-90.9%
Net Income	-$108M	-$58M	-85.8%